Next generation plasma proteome profiling to monitor health and disease

Nat Commun. 2021 May 3;12(1):2493. doi: 10.1038/s41467-021-22767-z.


The need for precision medicine approaches to monitor health and disease makes it important to develop sensitive and accurate assays for proteome profiles in blood. Here, we describe an approach for plasma profiling based on proximity extension assay combined with next generation sequencing. First, we analyze the variability of plasma profiles between and within healthy individuals in a longitudinal wellness study, including the influence of genetic variations on plasma levels. Second, we follow patients newly diagnosed with type 2 diabetes before and during therapeutic intervention using plasma proteome profiling. The studies show that healthy individuals have a unique and stable proteome profile and indicate that a panel of proteins could potentially be used for early diagnosis of diabetes, including stratification of patients with regards to response to metformin treatment. Although validation in larger cohorts is needed, the analysis demonstrates the usefulness of comprehensive plasma profiling for precision medicine efforts.

MeSH terms

  • Aged
  • Blood Proteins / analysis*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Diabetes Mellitus, Type 2 / genetics
  • Early Diagnosis
  • Female
  • Genetic Variation / genetics
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Longitudinal Studies
  • Male
  • Metformin / therapeutic use
  • Middle Aged
  • Plasma / chemistry*
  • Precision Medicine / methods
  • Proteome / analysis*
  • Proteomics / methods


  • Blood Proteins
  • Hypoglycemic Agents
  • Proteome
  • Metformin